Abnormal expression of multiple proteins predicts cancer‑specific mortality in patients with high‑grade non‑muscle‑invasive bladder cancer treated with transurethral resection

Tsumura,Hideyasu; Matsumoto,Kazumasa; Sato,Yuichi; Ikeda,Masaomi; Fujita,Tetsuo; Satoh,Takefumi; Iwamura,Masatsugu

doi:10.3892/mco.2013.92

Abnormal expression of multiple proteins predicts cancer‑specific mortality in patients with high‑grade non‑muscle‑invasive bladder cancer treated with transurethral resection

Authors:
- Hideyasu Tsumura
- Kazumasa Matsumoto
- Yuichi Sato
- Masaomi Ikeda
- Tetsuo Fujita
- Takefumi Satoh
- Masatsugu Iwamura
View Affiliations

Affiliations: Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Department of Molecular Diagnostics, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: March 14, 2013 https://doi.org/10.3892/mco.2013.92
Pages: 473-479

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High‑grade non‑muscle‑invasive bladder urothelial carcinoma leads to various outcomes. It can cause death even after radical cystectomy and is treated only by transurethral resection (TUR). In the present study, we aimed to determine whether the molecular markers E‑cadherin, coxsackie adenovirus receptor (CAR), S100A4 and uroplakin III are associated with clinicopathological outcomes in patients with high‑grade non‑muscle invasive bladder cancer (NMIBC) treated with TUR. Immunohistochemical staining was performed on serial sections from specimens obtained from 77 patients. Expression patterns were stratified according to the number of abnormally expressed markers: 0‑1 or ≥2. The median follow‑up time was 56 months (range, 3‑287). The results from the present study indicated that expression of E‑cadherin, CAR, S100A4 and uroplakin III was abnormal in 16, 17, 27 and 61% of tumors, respectively. Results of the log‑rank test revealed that patients with abnormal expression of multiple molecular markers had a significantly increased risk of bladder cancer‑specific mortality (P=0.016). The 5‑year cancer‑specific survival rates were 91 and 66% for patients with 0‑1 and ≥2 molecular markers, respectively. No individual marker was associated with disease prognosis. Multivariate models that included clinicopathological outcomes and classified molecular markers indicated that abnormal expression of multiple molecular markers and lack of bacillus Calmette‑Guérin (BCG) instillation are predictors of cancer‑specific death (P=0.046 and 0.029, respectively). Abnormal expression of multiple molecular markers is a strong predictor of mortality in bladder cancer patients undergoing TUR, suggesting that high‑grade non‑muscle‑invasive cancer is characterized by a variety of pathophysiological pathways. A combination of molecular markers may be useful in a minimally invasive modality for determining prognosis.

View Figures

View References

1.	Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L and Studer UE: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 169:96–100. 2003. View Article : Google Scholar
2.	Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49:466–465. 2006. View Article : Google Scholar
3.	Malavaud B: T1G3 bladder tumours: the case for radical cystectomy. Eur Urol. 45:406–410. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Turner W: T1G3 bladder tumours: the case for conservative treatment. Eur Urol. 45:401–405. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Agerbaek M, Alsner J, Marcussen N, Lundbeck F and Von der Maase H: Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol. 50:777–785. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Matsumoto K, Irie A, Satoh T, et al: Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 70:602–607. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Matsumoto K, Satoh T, Irie A, et al: Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 72:444–449. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Heimann R, Lan F, McBride R and Hellman S: Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 60:298–304. 2000.PubMed/NCBI
9.	Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O and Maelandsmo GM: Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 17:990–997. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI and Hsieh JT: The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res. 61:6592–6600. 2001.
11.	Sherbet GV and Lakshmi MS: S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res. 18:2415–2421. 1998.PubMed/NCBI
12.	Huang HY, Shariat SF, Sun TT, et al: Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol. 38:1703–1713. 2007. View Article : Google Scholar
13.	Matsumoto K, Shariat SF, Ayala GE, Rauen KA and Lerner SP: Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 66:441–446. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Matsumoto K, Kikuchi E, Horiguchi Y, et al: Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods. Urology. 75:1385–1390. 2010.
15.	Zieger K, Wolf H, Olsen PR and Hojgaard K: Long-term survival of patients with bladder tumours: the significance of risk factors. Br J Urol. 82:667–672. 1998. View Article : Google Scholar : PubMed/NCBI
16.	Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F and Vicente-Rodriguez J: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 164:680–684. 2000. View Article : Google Scholar : PubMed/NCBI
17.	van den Bosch S and Alfred Witjes J: Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 60:493–500. 2011.PubMed/NCBI
18.	Herr HW and Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 166:1296–1299. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Park J, Song C, Shin E, Hong JH, Kim CS and Ahn H: Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. Jul 20–2011, (Epub ahead of print).
20.	Lacombe L, Dalbagni G, Zhang ZF, et al: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol. 14:2646–2652. 1996.
21.	Schmitz-Drager BJ, Goebell PJ, Ebert T and Fradet Y: p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol. 38:691–699. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Alvarez-Mugica M, Cebrian V, Fernandez-Gomez JM, Fresno F, Escaf S and Sanchez-Carbayo M: Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol. 184:1507–1513. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Herr HW and Donat SM: A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 97:1194–1198. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Schwaibold HE, Sivalingam S, May F and Hartung R: The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97:1199–1201. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Decobert M, LaRue H, Harel F, Meyer F, Fradet Y and Lacombe L: Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer. 113:710–716. 2008. View Article : Google Scholar : PubMed/NCBI